Hanson & Doremus Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Hanson & Doremus Investment Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$129K	Hold	818	–	–	0.01%	246
2026 Q1	$104K	Hold	818	–	–	0.01%	257
2025 Q4	$100K	Hold	818	–	–	0.01%	261
2025 Q3	$82K	Sell	818 -482	-37%	-$43.4K	0.01%	276
2025 Q2	$108K	Sell	1,300 -355	-21%	-$28.3K	0.01%	255
2025 Q1	$134K	Sell	1,655 -1,924	-54%	-$172K	0.02%	224
2024 Q4	$322K	Sell	3,579 -1,346	-27%	-$130K	0.05%	146
2024 Q3	$487K	Sell	4,925 -2,877	-37%	-$283K	0.08%	110
2024 Q2	$723K	Sell	7,802 -1,107	-12%	-$99.3K	0.12%	90
2024 Q1	$845K	Sell	8,909 -4,697	-35%	-$436K	0.15%	84
2023 Q4	$1.22M	Sell	13,606 -9,706	-42%	-$721K	0.23%	72
2023 Q3	$1.7M	Sell	23,312 -544	-2%	-$43.5K	0.35%	60
2023 Q2	$1.99M	Buy	23,856 +1,534	+7%	+$128K	0.41%	50
2023 Q1	$1.7M	Buy	22,322 +351	+2%	+$29.1K	0.38%	56
2022 Q4	$1.82M	Buy	21,971 +1,885	+9%	+$153K	0.39%	58
2022 Q3	$1.59M	Buy	20,086 +4,468	+29%	+$377K	0.41%	54
2022 Q2	$1.16M	Buy	15,618 +2,405	+18%	+$181K	0.28%	72
2022 Q1	$1.19M	Buy	13,213 +1,472	+13%	+$136K	0.26%	73
2021 Q4	$1.31M	Buy	11,741 +1,094	+10%	+$132K	0.28%	65
2021 Q3	$1.34M	Buy	10,647 +2,055	+24%	+$265K	0.31%	65
2021 Q2	$957K	Sell	8,592 -760	-8%	-$99.9K	0.29%	70
2021 Q1	$1.27M	Buy	9,352 +530	+6%	+$79.4K	0.29%	73
2020 Q4	$1.24M	Buy	8,822 +230	+3%	+$29.5K	0.31%	63
2020 Q3	$957K	Buy	8,592 +1,461	+20%	+$164K	0.29%	70
2020 Q2	$798K	Sell	7,131 -93	-1%	-$9.16K	0.25%	80
2020 Q1	$559K	Buy	7,224 +1,606	+29%	+$142K	0.19%	94
2019 Q4	$534K	Buy	5,618 +1,259	+29%	+$109K	0.15%	110
2019 Q3	$332K	Buy	4,359 +4,230	+3,279%	+$352K	0.1%	133
2019 Q2	$11K	Buy	+129	New	+$11K	﹤0.01%	411

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Hanson & Doremus Investment Management's XBI Position: Q2 2026 in Review

Hanson & Doremus Investment Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 818 shares worth $129K. The position accounts for 0.01% of the portfolio, ranked #246.

Hanson & Doremus Investment Management first reported a position in XBI in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.99M in Q2 2023. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Hanson & Doremus Investment Management held 818 shares of State Street SPDR S&P Biotech ETF worth $129K as of Q2 2026.
Hanson & Doremus Investment Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #246 holding.
Hanson & Doremus Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2019 and has held it in 29 quarters since.
Hanson & Doremus Investment Management's State Street SPDR S&P Biotech ETF position peaked at $1.99M in Q2 2023.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.